Login to Your Account



Least of Genzyme's Concerns

Protalix: $115M Gaucher's Deal with Pfizer is Just the Beginning

By Trista Morrison


Wednesday, December 2, 2009
Shares of Protalix BioTherapeutics Inc. dipped 13.7 percent on Tuesday after the biotech unveiled a $115 million profit-sharing deal with Pfizer Inc. for Gaucher's disease drug Uplyso (taliglucerase alfa). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription